These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20824430)

  • 41. [Enhancement of HSP-MUC1 antitumor activity by type C CpG-ODN BW005].
    Wang XJ; Wang ZB; Wei HF; Wu XL; Wang L; Yu YL; Wang LY
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):338-40. PubMed ID: 17428390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
    Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
    ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune response of the female rat genital tract after oral and local immunization with keyhole limpet hemocyanin conjugated to the cholera toxin B subunit.
    Menge AC; Michalek SM; Russell MW; Mestecky J
    Infect Immun; 1993 May; 61(5):2162-71. PubMed ID: 8478106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
    Mukherjee P; Pathangey LB; Bradley JB; Tinder TL; Basu GD; Akporiaye ET; Gendler SJ
    Vaccine; 2007 Feb; 25(9):1607-18. PubMed ID: 17166639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice.
    Chen D; Koido S; Li Y; Gendler S; Gong J
    Breast Cancer Res Treat; 2000 Mar; 60(2):107-15. PubMed ID: 10845273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Production of a recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes.
    Yuki Y; Hara-Yakoyama C; Guadiz AA; Udaka S; Kiyono H; Chatterjee S
    Biotechnol Bioeng; 2005 Dec; 92(7):803-9. PubMed ID: 16142801
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice.
    Lees CJ; Apostolopoulos V; Acres B; Ramshaw I; Ramsay A; Ong CS; McKenzie IF
    Vaccine; 2000 Sep; 19(2-3):158-62. PubMed ID: 10930667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Effect of Different Immunization Cycles of a Recombinant Mucin1-Maltose-Binding Protein Vaccine on T Cell Responses to B16-MUC1 Melanoma in Mice.
    Zhou H; Zhang Z; Liu G; Jiang M; Wang J; Liu Y; Tai G
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823603
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.
    Gong J; Chen D; Kashiwaba M; Li Y; Chen L; Takeuchi H; Qu H; Rowse GJ; Gendler SJ; Kufe D
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6279-83. PubMed ID: 9600956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines.
    Acres B; Apostolopoulos V; Balloul JM; Wreschner D; Xing PX; Ali-Hadji D; Bizouarne N; Kieny MP; McKenzie IF
    Cancer Immunol Immunother; 2000 Jan; 48(10):588-94. PubMed ID: 10630311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases.
    Langridge W; Dénes B; Fodor I
    Curr Opin Investig Drugs; 2010 Aug; 11(8):919-28. PubMed ID: 20721834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity of a cholera toxin B subunit Porphyromonas gingivalis fimbrial antigen fusion protein expressed in E. coli.
    Kim TG; Huy NX; Kim MY; Jeong DK; Jang YS; Yang MS; Langridge WH; Lee JY
    Mol Biotechnol; 2009 Feb; 41(2):157-64. PubMed ID: 18807220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of organ site and tumor cell type on MUC1-specific tumor immunity.
    Morikane K; Tempero R; Sivinski CL; Kitajima S; Gendler SJ; Hollingsworth MA
    Int Immunol; 2001 Feb; 13(2):233-40. PubMed ID: 11157856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from Helicobacter pylori urease A subunit.
    Guo L; Li X; Tang F; He Y; Xing Y; Deng X; Xi T
    Appl Microbiol Biotechnol; 2012 Mar; 93(5):1937-45. PubMed ID: 22134639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.
    Zhang P; Lewis JP; Michalek SM; Katz J
    Vaccine; 2007 Aug; 25(33):6201-10. PubMed ID: 17629367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N
    Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo.
    Sadeghi H; Bregenholt S; Wegmann D; Petersen JS; Holmgren J; Lebens M
    Immunology; 2002 Jun; 106(2):237-45. PubMed ID: 12047753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
    Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
    Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.